Kivizidiale (Timolol, Travoprost)

Kivizidiale is used in the management of ocular conditions that require reduction of intraocular pressure.

• Open-angle glaucoma: lowers intraocular pressure to prevent progression of optic nerve damage.
• Ocular hypertension: reduces intraocular pressure to lower the risk of developing glaucoma.
• Secondary open-angle glaucoma: helps control pressure when caused by other ocular diseases.

• Timolol, a non‑selective beta‑adrenergic antagonist, decreases aqueous humor production by blocking β‑receptors in the ciliary body. Travoprost, a prostaglandin F2α analogue, increases uveoscleral outflow by remodeling extracellular matrix within the trabecular meshwork. The combined action results in a net reduction of intraocular pressure, addressing both production and drainage pathways. This dual mechanism provides sustained pressure control with once‑daily dosing in most patients.

Kivizidiale may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Eye irritation: mild burning or stinging after instillation.
• Blurred vision: temporary reduction in visual clarity.
• Redness of the eye: conjunctival hyperemia.
• Dry eye: decreased tear production or discomfort.
• Itching or foreign‑body sensation.

Serious or Rare Side Effects

• Severe allergic reaction: angioedema or anaphylaxis.
• Significant bradycardia: marked slowing of heart rate.
• Bronchospasm: worsening of asthma or COPD.
• Persistent eye pain or inflammation.
• Vision loss: sudden decrease in visual acuity.

Before prescribing Kivizidiale, clinicians should evaluate patient-specific risk factors and monitor for adverse events.

• Assess cardiovascular status: avoid in patients with severe bradycardia or heart block.
• Screen for respiratory disease: use cautiously in asthma or COPD.
• Monitor intraocular pressure: adjust therapy if target pressure not achieved.
• Avoid concurrent use with other beta‑blocker eye drops: may increase systemic absorption.
• Pregnancy and lactation: safety not established; weigh benefits and risks.
• Store at room temperature: keep in the original container, protect from light and moisture.

Kivizidiale can interact with systemic and ocular medications; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Systemic beta‑blockers: additive bradycardia and hypotension.
• Non‑selective beta‑blocker inhalers: increased risk of bronchospasm.
• MAO inhibitors: potential hypertensive crisis with prostaglandin analog component.
• Other prostaglandin analog eye drops: risk of excessive intraocular pressure lowering.

Moderate Interactions (Monitor Closely)

• Anticholinergic eye drops: may reduce timolol efficacy.
• Topical corticosteroids: may counteract IOP‑lowering effect.
• Diuretics: monitor electrolytes if systemic absorption occurs.